{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:19:51Z","timestamp":1795043991907,"version":"4.10.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01295-y","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:59:29Z","timestamp":1790629169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics and Exposure\u2013response Analysis of Durvalumab in Patients with Limited-stage Small-cell Lung Cancer in the Phase 3 ADRIATIC Study"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1772-0744","authenticated-orcid":false,"given":"Hong","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8899-6356","authenticated-orcid":false,"given":"Becky Jiajia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7883-3866","authenticated-orcid":false,"given":"Yu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4229-1470","authenticated-orcid":false,"given":"Yan-Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4951-6612","authenticated-orcid":false,"given":"Priti","family":"Chugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8505-568X","authenticated-orcid":false,"given":"Ed","family":"Casson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3792-6432","authenticated-orcid":false,"given":"KyoungSoo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5046-9008","authenticated-orcid":false,"given":"Song","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2673-1069","authenticated-orcid":false,"given":"Diansong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0246-3132","authenticated-orcid":false,"given":"Peiming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9259-7064","authenticated-orcid":false,"given":"Chunling","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"5","key":"1295_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","volume":"66","author":"AV Balar","year":"2017","unstructured":"Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017;66(5):551\u201364.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"1295_CR2","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart R, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052\u201362.","journal-title":"Cancer Immunol Res"},{"issue":"24","key":"1295_CR3","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350.","journal-title":"N Engl J Med"},{"issue":"18","key":"1295_CR4","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(18):1672\u201384.","journal-title":"N Engl J Med"},{"issue":"6","key":"1295_CR5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2023;41(6):1213\u201327.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1295_CR6","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N Engl J Med. 2024;391(14):1313\u201327.","journal-title":"N Engl J Med"},{"issue":"8","key":"1295_CR7","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.","journal-title":"NEJM Evid"},{"issue":"2","key":"1295_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408.","journal-title":"ESMO Open"},{"issue":"10212","key":"1295_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339.","journal-title":"Lancet"},{"issue":"8","key":"1295_CR10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"1295_CR11","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"3","key":"1295_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.23.02132","volume":"42","author":"SN Westin","year":"2024","unstructured":"Westin SN, et al. Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024;42(3):283\u201399.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1295_CR13","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s12094-023-03216-3","volume":"25","author":"R Garc\u00eda-Campelo","year":"2023","unstructured":"Garc\u00eda-Campelo R, et al. SEOM-GECP clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). Clin Transl Oncol. 2023;25(9):2679\u201391.","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"1295_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.lungcan.2011.08.004","volume":"75","author":"SP Riaz","year":"2012","unstructured":"Riaz SP, et al. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer. 2012;75(3):280\u20134.","journal-title":"Lung Cancer"},{"issue":"1","key":"1295_CR15","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","volume":"7","author":"S Wang","year":"2017","unstructured":"Wang S, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep. 2017;7(1):1339.","journal-title":"Sci Rep"},{"issue":"11","key":"1295_CR16","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1111\/cas.70188","volume":"116","author":"Y Zenke","year":"2025","unstructured":"Zenke Y, et al. Durvalumab post concurrent chemoradiotherapy in Japanese patients with limited-stage small-cell lung cancer in the phase 3 ADRIATIC trial. Cancer Sci. 2025;116(11):3171\u201384.","journal-title":"Cancer Sci"},{"key":"1295_CR17","doi-asserted-by":"crossref","unstructured":"Zhao X, et al. Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study. Br J Clin Pharmacol. 2026;92(3):980\u201396.","DOI":"10.1002\/bcp.70287"},{"issue":"1","key":"1295_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00280-024-04743-8","volume":"95","author":"A Abegesah","year":"2025","unstructured":"Abegesah A, et al. Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2025;95(1):23.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1295_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cpt.982","volume":"103","author":"PG Baverel","year":"2018","unstructured":"Baverel PG, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103(4):631\u201342.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1295_CR20","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/cpt.3063","volume":"114","author":"JZ He","year":"2023","unstructured":"He JZ, et al. Population pharmacokinetics and exposure-response analysis for the CTLA-4 inhibitor tremelimumab in metastatic NSCLC patients in the phase III POSEIDON study. Clin Pharmacol Ther. 2023;114(6):1375\u201386.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1295_CR21","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/jcph.2288","volume":"63","author":"K Lim","year":"2023","unstructured":"Lim K, et al. Population pharmacokinetics and exposure-response analysis of tremelimumab 300 mg single dose combined with durvalumab 1500 mg Q4W (STRIDE) in patients with unresectable hepatocellular carcinoma. J Clin Pharmacol. 2023;63(11):1221\u201331.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1295_CR22","doi-asserted-by":"publisher","first-page":"S508","DOI":"10.1016\/j.jtho.2021.01.891","volume":"16","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, et al. P48.21 Population pharmacokinetics and exposure-response with durvalumab plus platinum-etoposide in ES-SCLC: results from CASPIAN. J Thorac Oncol. 2021;16(3):S508.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1295_CR23","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.jtho.2019.06.010","volume":"14","author":"SJ Antonia","year":"2019","unstructured":"Antonia SJ, et al. Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC. J Thorac Oncol. 2019;14(10):1794\u2013806.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1295_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","volume":"19","author":"MC Garassino","year":"2018","unstructured":"Garassino MC, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19(4):521\u201336.","journal-title":"Lancet Oncol"},{"issue":"20","key":"1295_CR25","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"27","key":"1295_CR26","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","volume":"39","author":"RK Kelley","year":"2021","unstructured":"Kelley RK, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study. J Clin Oncol. 2021;39(27):2991\u20133001.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1295_CR27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6(9):576\u201388.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1295_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1669979","volume":"16","author":"BC Remaily","year":"2025","unstructured":"Remaily BC, et al. Tumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearance. Front Immunol. 2025;16:1669979.","journal-title":"Front Immunol"},{"issue":"12","key":"1295_CR29","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/psp4.70119","volume":"14","author":"X Yin","year":"2025","unstructured":"Yin X, et al. Evaluation and mitigation of time-dependent confounding effects in conventional exposure-response analyses for oncology drugs. CPT Pharmacomet Syst Pharmacol. 2025;14(12):2118\u201327.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"1295_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/psp4.12139","volume":"6","author":"M Ahamadi","year":"2017","unstructured":"Ahamadi M, et al. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacomet Syst Pharmacol. 2017;6(1):49\u201357.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"1295_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","volume":"6","author":"G Bajaj","year":"2017","unstructured":"Bajaj G, et al. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacomet Syst Pharmacol. 2017;6(1):58\u201366.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"5","key":"1295_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cpt.656","volume":"101","author":"C Liu","year":"2017","unstructured":"Liu C, et al. Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther. 2017;101(5):657\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1295_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","volume":"44","author":"H Li","year":"2017","unstructured":"Li H, et al. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn. 2017;44(5):403\u201314.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01295-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:14:48Z","timestamp":1795043688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01295-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01295-y","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hong Su, Jiajia Zhao, Yu Fu, Yan-Yan Zhang, Priti Chugh, Ed Casson, Song Ren, Diansong Zhou, Peiming Ma, and Chunling Fan report employment with AstraZeneca. KyoungSoo Lim and Yan-Yan Zhang report former employment with AstraZeneca. Song Ren, Diansong Zhou, Peiming Ma, and Chunling Fan report ownership of stock\/shares in AstraZeneca.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"162"}}